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ABSTRACT 
Objective: to analyze the predictive value of coronary CT angiography and to model and 
validate an optimized score for prognosis of 2-year survival based on a patient population 
with suspected coronary artery disease (CAD). 
Background: Coronary CT angiography (CCTA) carries important prognostic information in 
addition to the detection of obstructive coronary artery disease. But it is still unclear how the 
results of CCTA should be interpreted in the context of clinical risk predictors 
Methods: The analysis is based on a test sample of 17,793 patients and a validation sample 
of 2,506 patients, all with suspected CAD, from the international CONFIRM registry. Based 
on CCTA data and clinical risk scores, an optimized score was modeled. The endpoint was all 
cause mortality. 
Results: During a median follow-up of 2.3 years, 347 patients died. Best CCTA parameter 
for prediction of mortality was the number of proximal segments with mixed or calcified 
plaques (C-index 0.64, p<0.0001) and the number of proximal segments with a stenosis 
>50% (C-index 0.56, p=0.002). In an optimized score including both parameters, CCTA 
significantly improved overall risk prediction beyond NCEP ATP III score as best clinical 
score. According to this score, a proximal segment with either a mixed or calcified plaque or 
a stenosis >50% is equivalent to a 5 year increase in age or the risk of smoking. 
Conclusion: In CCTA, both plaque burden and stenosis, particularly in proximal segments, 
carry incremental prognostic value. A prognostic score based on this data can improve risk 
prediction beyond clinical risk scores. 
 
KEYWORDS 
Coronary CT Angiography 
Coronary artery disease 
Prognosis 
 
ABBREVIATIONS 
CCTA  coronary computed tomography angiography 
CAD coronary artery disease 
NRI net reclassification improvement 
IQR inter quartile range 
95%CI 95% confidence interval 
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INTRODUCTION 
Coronary CT angiography is commonly accepted as clinically useful modality for the 
diagnosis and exclusion of obstructive CAD particularly in patients with intermediate pre-test 
risk (1,2). In addition to stenosis assessment, it allows for the non-invasive detection and 
further characterization of coronary plaques even in the absence of obstruction. While the 
presence of obstructive CAD is the cornerstone for further medical and invasive therapy, 
multiple smaller studies (3-14) have revealed that non-obstructive plaques may have a 
significant influence on prognosis. Nevertheless, due to the small number of patients in these 
studies, only limited data exist concerning the best parameters to describe severity and extent 
of coronary atherosclerosis in the context of prognosis. 
The objective of this study was to analyze the predictive value of different parameters to 
assess the presence, extent, and type of coronary atherosclerotic plaque by CT angiography 
and to model and validate an optimized prognostic score for 2-year survival in a large 
population of patients with suspected CAD from an international multicenter registry. 
METHODS 
Study population 
The CONFIRM registry is an international, multicenter, observational registry collecting 
clinical, procedural and follow-up data of patients undergoing coronary CT angiography for 
clinically indicated reasons currently comprising 31,807 patients from 17 participating sites in 
7 countries (United States, Canada, Germany, Switzerland, Italy, Austria, and South Korea).  
The CONFIRM registry contains two sections. Section 1 comprises 27,125 patients from 
12 sites enrolled between January 2004 and May 2010 and was locked in October 2010. This 
section served as the test sample. Section 2 comprises 4682 patients from 5 sites enrolled 
between July 2005 and October 2010 (database locked in May 2011) and served as validation 
sample. Institutional review board approval was obtained at each center.  
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Inclusion criteria for this analysis were: (1) patients with suspected but not proven 
coronary artery disease, (2) assessment of both luminal stenosis as well as presence and 
composition of plaque in coronary CT angiography, and (3) a follow-up of at least 90 days. 
The exclusion criterion of known coronary artery disease was defined as patient reported past 
myocardial infarction, coronary revascularization or presence of any stents or grafts/graft 
stenosis as recorded by CT findings. 
A detailed description of the methods is published elsewhere (15). A structured interview 
was conducted before the investigation to collect information on symptoms attributable to 
cardiac disease and the presence of cardiovascular risk factors. Systemic arterial hypertension 
was defined as a documented history of blood pressure >140 mmHg or treatment with anti-
hypertensive medications. Diabetes mellitus was defined by diagnosis of diabetes made 
previously by a physician and/or use of insulin or oral hypoglycemic agents. A positive 
smoking history was defined as current smoking or cessation of smoking within three months 
of testing. Family history of premature coronary heart disease was defined as history of 
myocardial infarction of a first degree relative below the age of 55 for male and 65 for female 
relatives. In addition blood cholesterol levels of the lipid test nearest to the index examination 
were recorded; the median time interval between CT exam and lipid test was 39 days in the 
test sample and 70 days in the validation sample.  From these data, the NCEP ATP III 
score(16), the Framingham risk score(17) and the Morise clinical risk score(18) were 
calculated. 
Image acquisition and analysis 
All coronary CT angiography investigations were performed on multiple-row detector CT 
scanners with at least 64 simultaneously acquired slices and the imaging protocol adhered to 
the Society of Cardiovascular Computed Tomography guidelines on appropriateness and 
performance of CCTA, as far as available at the time of scanning (2,19,20). Patient 
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preparation, data acquisition and analysis were according to the local sites’ institutional 
policies. 
Coronary segments were scored visually for the presence and composition of coronary 
plaque and degree of luminal stenosis using a 16-segment coronary artery model (21). In each 
coronary artery segment, plaques were classified as noncalcified, mixed or calcified. The 
presence of coronary calcification was determined visually in the contrast-enhanced data set. 
Noncalcified plaque was defined as a tissue structure >1mm2 that could be clearly 
discriminated from the vessel lumen and surrounding tissue, with a density below the contrast 
enhanced blood pool. Plaques meeting this definition and in addition showing calcified areas 
of any extent were classified as mixed plaques. The severity of luminal diameter stenosis was 
scored visually as none (0% luminal stenosis), mild (1 to 49% luminal stenosis), moderate (50 
to 69% luminal stenosis), or severe (≥70% luminal stenosis). For further analysis, the 
numbers of segments with a specific plaque composition or a specific luminal stenosis were 
summed up. The number of segments with any plaque or stenosis is equivalent to the segment 
involvement score proposed by Min (7). 
From each of these base scores optimized jeopardy scores were derived, assessing only 
proximal segments (proximal and mid RCA, left main, proximal and mid left anterior 
descendent, proximal circumflex, first obtuse marginal branch) and describing the result in 3 
categories: no proximal segment affected, 1 proximal segment affected, ≥2 proximal 
segments affected.   
Using the best clinical risk score and the most predictive CCTA parameters the combined 
CONFIRM risk score was modeled. 
Follow-up & study endpoint 
The primary endpoint of the study was time to death from any cause. In US-sites death 
status was ascertained by querying the Social Security Death Index. In non-US-sites follow-
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up data was collected by mail or telephone contact with the patients or their families; events 
were verified by hospital records or contacts with the attending physician. 
Statistical Analysis 
Categorical variables were expressed as frequencies and percentages, continuous 
variables were expressed as means and standard deviations. All statistical evaluations are 
based on survival using the Kaplan-Meier method; hazard ratios (for difference between 75th 
and 25th percentile) and multivariable analyses were calculated with the Cox proportional 
hazard model. Significant contribution to a multivariable model was tested using Akaike's 
information criterion. Concordance (C)-indices were calculated from time-to-event data as 
proposed by Harrell (22). The incremental predictive value was assessed using the net 
reclassification improvement (NRI) according to Pencina (23). For modeling the CONFIRM 
risk score, both internal validation by randomly splitting the test sample and external 
validation on an independent dataset were performed, the modeling process is described in 
detail in an online statistical supplement. Statistical significance was accepted for two-sided 
p-values <0.05. The statistical package R version 2.10.1(24) including the package 
Design(25) was used for statistical analysis.  
RESULTS 
Study population, clinical characteristics and follow-up 
Out of 27,125 patients in the test sample, 2,350 patients were excluded because of known 
CAD, 814 patients because of missing data on contrast enhanced coronary angiography 
(mainly because only calcium scoring was performed), 5844 patients from sites not assessing 
plaque characterization, 1 patient because of missing information on age and 323 patients 
because available follow-up was missing or < 90 days. Hence, the study population for the 
test sample comprised 17,793 patients. Out of 4,682 patients in the validation sample, 377 
patients were excluded because of known CAD, 447 patients because of missing data on 
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contrast enhanced coronary angiography, 1334 patients from sites not assessing plaque 
characterization, 5 patient because of missing information on age and 13 patients because 
available follow-up was missing or <90 days. Hence, the study population for the test sample 
comprised 2,506 patients. 
Median age of the patients was 58 years [IQR 49 to 66 years] in the test sample and 57 
years [IQR 48 to 65 years] in the validation sample (p<0.0001), Gender distribution was 
similar in both groups with 9440 males (53%) in the test sample and 1319 males (53%) in the 
validation sample (p=0.70). There were significant differences in risk profile and symptoms 
on presentation, as can be seen in Table 1. The pre-test risk was predominantly low when 
assessed by the NCEP ATP III and Framingham score and predominantly intermediate 
according to the Morise score. 
During a median follow-up of 2.3 years [IQR 1.6 to 3.1 years] in the test sample, 317 
patients died. This corresponds to an annual mortality rate of 0.75% (95% CI 0.67 to 0.82%). 
In the validation sample the median follow up was 1.5 years [IQR 1.0 to 2.8 years] and 30 
patients died resulting in an annual mortality rate of 0.63% (95% CI 0.45 to 0.91%). 
Predictive value of clinical risk scores 
All three clinical risk scores correlated significantly with outcome. The best was NCEP 
ATP III (c-index 0.706); followed by the Framingham risk (c-index 0.623) and then the 
Morise (c-index 0.618) scores (see also Table 2). The difference between NCEP ATP III and 
Framingham was significant (p<0.0001); all further analysis was therefore based on NCEP 
ATP III. 
Predictive value of coronary CT angiography 
Patients had 2.1±2.8 coronary segments affected by plaques, of which 0.3±0.9 (17%) 
were noncalcified, 0.8±1.6 (38%) mixed and 0.9±1.7 (45%) calcified. In a mean of 0.5±1.1 
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segments (22% of all segments with plaques) revealed a significant stenosis (>50% lumen 
reduction) and 0.2±0.6 (7%) a severe stenosis (>70% lumen reduction).  
All of these parameters correlated significantly with outcome except the number of 
segments with noncalcified plaques. After correction for clinical risk the correlation with 
outcome remained significant only for the total number of segments with plaque (c-index 
0.62, p<0.0001). The predictive value could be significantly increased by focusing on 
proximal segments only (p=0.0026 compared to the total number of segments with plaque) 
and further by only counting calcified or mixed plaque (p=0.0030 for improvement). While 
the number of all segments with stenosis >50% did not correlate significantly with outcome, 
the number of proximal segments with stenosis >50% was a significant predictor (c-index 
0.56, p=0.003). Adjusted risk stratification is summarized in Table 3 and graphically 
displayed in Figure 1. Compared with NCEP ATP III score (c-index 0.706) risk prediction 
could be improved both by the number of proximal segments with mixed or calcified plaques 
(c-index 0.741 for the combined model, p<0.0001 for improvement) and the number of 
proximal segments with stenosis >50% (c-index 0.734 for the combined model, p=0.003 for 
improvement).  
Combined Score 
An optimized score was modeled combining from clinical risk assessment and CCTA 
parameters which comprised three parameters: the NCEP ATP III score, the number of 
proximal segments with stenosis>50% and the number of proximal segments with either 
calcified or mixed plaques. This model could significantly improve prediction beyond the 
NCEP ATP III score both in the test sample (NRI 49%, p<0.0001) and in the validation 
sample (NRI 60%, p=0.0011). The model is summarized in Table 4, the incremental 
predictive value is visualized in Figure 2, and a detailed description of the modeling process 
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is provided as an online statistical supplement. An online calculator for the CONFIRM 
prognostic score is available at the internet address http://www.ctconfirm.org/risk. 
To be comparable with the NCEP APT III score, which assesses the risk for cardiac death 
or myocardial infarction instead of overall mortality as used in this study, cut-offs of 0.8% 
and 1.6% annual mortality rate between low and intermediate risk resp. intermediate and high 
risk were used. With these values, the annual mortality rate ranged from 0.32% (95%CI 
0.26% to 0.39%) for low risk to 1.3% (95%CI 1.1% to 1. 6%) for intermediate risk to 2.4% 
(95%CI 2.0% to 2.9%) for high risk in the test sample and from 0.29% (95%CI 0.15% to 
0.56%) for low risk to 1.1% (95%CI 0.64% to 2.0%) for intermediate risk to 1.6% (95%CI 
0.84% to 3.1%) for high risk in the validation sample. Using these risk categories, 32% of the 
patients in the test sample and 33% of the patients in the validation sample could be 
reclassified regarding their cardiovascular risk. In the test sample 3,909 patients (22.0%) were 
assigned to a lower risk and 1,774 patients (10.0%) were assigned to a higher risk. Similar 
percentages were found in the validation sample, as described in Figure 3 in more detail. 
DISCUSSION 
It is well known from single center studies, that in addition to the degree of stenosis, the 
extent of coronary atherosclerosis as documented by coronary CT angiography is an 
important prognostic factor. Ostrom et al. (10) demonstrated a correlation between mortality 
and the number of involved vessels both for non-obstructive and obstructive lesions. Min et 
al. (7) found that a segment involvement score counting segments which exhibited plaque, 
irrespective of stenosis severity, had a particularly good correlation with survival. Our 
analysis of 20,299 patients from the international CONFIRM registry reaffirms the predictive 
value of segmental plaque burden above and beyond the degree of stenosis. 
Multiple studies both on invasive angiography and CCTA have shown that diseased 
proximal segments are prognostically more relevant than distal ones and a number of 
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jeopardy scores with varying complexity have been proposed to account for this fact 
(7,26,27). In our patient population, we identified 7 coronary segments as being important for 
prognosis: The left main, the proximal and mid left anterior descending, the proximal 
circumflex and the first obtuse marginal branch, and the proximal and mid right coronary 
artery. By focusing only on the presence of atherosclerotic plaques in these segments the 
predictive value of CCTA could be improved significantly. 
Regarding plaque composition we found that exclusively noncalcified plaques had no 
significant correlation with mortality. Furthermore, a predictive model considering only 
mixed or calcified plaques was significantly better than a model considering all plaques. This 
result is surprising, since non-calcified plaques components are often considered more 
vulnerable to future rupture, and hence future myocardial infarction and death (28,29). A 
possible explanation for this finding could be that CCTA is not able to identify the rupture 
prone plaques and that vulnerable plaques are only a small fraction of all noncalcified plaques 
identified by coronary CT angiography. Taking into account the size of this study population, 
this finding deserves further analysis beyond the scope of the present report. 
Based on the current study, we identified the two parameters “number of proximal 
segments with mixed or calcified plaques” and “number of proximal segments with 
stenosis>50%” as the best CCTA parameter improving outcome predicting beyond clinical 
risk scores.  
Putting these parameters in context with the clinical risk factors as assessed by the NCEP 
ATP III score which was the best clinical risk predictor in our cohort, we found that both a 
proximal segment with mixed or calcified plaques and a proximal segment with 
stenosis>50% are equivalent to 2.8 score points in the published point model of the NCEP 
ATP III score (16) which is in the same range as an increase in age of 5 years or the average 
risk of smoking. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
12 
 
These results confirm the incremental prognostic value of CCTA beyond clinical risk 
factors and allow for a quantification of the risk associated with proximal plaque in CCTA. 
This risk is not only significant but also substantial and in the same ranges as relevant clinical 
risk factors like hypertension or smoking. Thus CCTA can describe the vascular age and the 
associated risk for mortality. 
Assessing the prognosis of a typical patient undergoing CCTA having a low to 
intermediate risk for coronary artery disease is difficult. Most of the established risk scores 
like Framingham risk score are tested on asymptomatic individuals and aim for the long term 
prediction of symptomatic CAD. Both criteria are not met in the patient group at interest. 
Even the Morise score, which is designed to the risk of all-cause mortality in symptomatic 
patients, had a limited predictive value in our study population. Obviously, this score, which 
was validated on a patient population with a higher annual mortality (1.1% vs. 0.75% in our 
study), cannot be applied to a low to intermediate risk population without restrictions. 
Being based on the largest patient population currently available, it is our opinion that the 
proposed combined score now clearly improves risk prediction beyond established clinical 
risk scores and allows for a robust risk assessment of patients with suspected CAD 
undergoing CCTA.  
This may facilitate a more targeted prevention regimen for coronary artery disease.  
Patients at high risk according to the new score have an annual mortality risk of >1.0% and an 
intensified preventive regimen including both lifestyle change and medication seems logical. 
In low-risk patients, there might be the possibility for reducing preventive efforts. However, 
we have limited information on medication during follow-up in our study, and this option 
must be validated by prospective outcome studies. 
An analysis of invasive angiographies and revascularizations during follow-up is beyond 
the scope of this study and is covered by a companion paper (30). 
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Limitations 
This is an observational multicenter study. Pre-test risk differs significantly between sites. 
This might confound the results of the study. However, the risk score performed significantly 
in all sites (data supplied in the statistical supplement) demonstrating the broad applicability 
of the results. There is only limited information regarding lifestyle modification and medical 
and interventional therapy during follow-up so that a correction for its confounding influence 
was not possible. This is an inherent limitation of the study design and can only be 
circumvented by prospective outcome trials. Nevertheless, the results of this study are based 
on the largest currently available pooled patient population, and they can serve as a robust 
base for the design and initiation of such trials. 
The weak correlation between noncalcified plaques and outcome may be caused by the 
heterogeneity of the study population and the equipment used. Detection of non-calcified 
plaques is not always easy, particularly with suboptimal image quality and may be influenced 
by filters used for image presentation, which vary considerably between vendors. In addition, 
advanced reconstruction algorithms were not widely available at the time the scans of this 
study were performed. 
Conclusion 
In patients undergoing CCTA, both atherosclerotic plaque burden and obstructive 
coronary disease, particularly in the proximal segments, carry incremental prognostic value 
beyond clinical risk factors. The increase in mortality risk associated with the presence of 
proximal coronary artery disease manifestation in CCTA is comparable with the risk of 
clinical risk factors like smoking or an increase in “vascular” age of 5 years. A predictive 
score combining CCTA parameters with clinical information significantly improves 
prediction compared to well established clinical risk scores and allows for a reclassification 
of about one third of the patients regarding their mortality risk. 
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FIGURE LEGENDS 
Figure 1 
Kaplan-Meier plot 
Survival probability dependent on proximal segments with calcified or mixed plaque (left) 
and proximal stenosis >50% (right), corrected for NCEP ATP III score. 
 
Figure 2 
ROC curve for all-cause mortality. 
Receiver-operator-characteristics of Morise, Framingham and NCEP ATP III clinical scores, 
and the optimized score (additionally including proximal segments with calcified or mixed 
plaque and proximal segments with stenosis>50%). Test sample on the left and validation 
sample on the right.  
 
Figure 3 
Reclassification of risk prediction 
Reclassification matrix between NCEP ATP III and optimized score for all patients in the test 
(top) and validation sample (second) and separated by outcome (death third, no death bottom, 
test sample only). 
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Table 1: Clinical Characteristics and Risk Factors 
 
Test sample 
n=17793 
Validation sample 
n=2506 
p value 
Age (years) 58 [49, 66] 57 [48, 65] <0.0001 
Male sex 9440 (53%) 1319 (53%) 0.70 
Hypertension 9029 (51%) 1432 (57%) <0.0001 
Diabetes 2668 (15%) 402 (16%) 0.17 
Total Cholesterol (mg/dl) 189 [162, 217] 196 [166, 226] <0.0001 
LDL Cholesterol (mg/dl) 115 [92, 140] 114 [89,141] 0.36 
HDL Cholesterol (mg/dl) 51 [42, 61] 52 [43, 64] 0.0003 
Current smoker 3634 (20%) 471 (19%) 0.059 
Family history for CAD 6174 (35%) 1136 (45%) <0.0001 
Angina pectoris   <0.0001 
   nonanginal chest pain 2316 (13%) 390 (16%)  
   atypical angina 6491 (37%) 476 (19%)  
   typical angina 3024 (17%) 553 (22%)  
Dyspnea on exertion 5919 (33%) 569 (23%) <0.0001 
NCEP ATP III risk 7.5 [2.5, 16.4] 6.4 [2.0, 16.6] 0.0013 
   Low risk (<10) 10522 (59%) 1523 (61%)  
   Intermediate risk (10-20) 3551 (20%) 433 (17%)  
   High risk (>20) 3720 (21%) 550 (22%)  
Framingham risk 9.8 [5.9, 15.9] 9.8 [5.7, 16.1] 0.49 
   Low risk (<10) 9022 (51%) 1263 (51%)  
   Intermediate risk (10-20) 5637 (32%) 790 (32%)  
   High risk (>20) 2951 (17%) 430 (17%)  
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Morise score 11 [9, 14] 11 [9, 13] 0.015 
   Low risk (<9) 3510 (20%) 486 (19%)  
   Intermediate risk (9-15) 12445 (70%) 1794 (72%)  
   High risk (>9) 1838 (10%) 226 (9%)  
Values are expressed as median [interquartile range] or occurrences (percentages), CAD 
denotes coronary artery disease.
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Table 2: predictive value of clinical risk scores in the test group 
score 
No death 
n=17476 
Death 
n=317 
Hazard ratio Chi² c-index p-value 
NCEP ATP III risk 9.4±7.7 15.5±8.2 3.01 [2.62, 3.45] 171 0.706 <0.001 
   Low risk (<10) 10437 (60%) 85 (27%)     
   Intermediate risk (10-20) 3460 (20%) 91 (29%)     
   High risk (>20) 3579 (20%) 141 (44%)     
Framingham risk 12.5±9.97 19.9±16.6 1.54 [1.44, 1.65] 118 0.623 <0.001 
   Low risk (<10) 8920 (52%) 104 (33%)     
   Intermediate risk (10-20) 5543 (32%) 94 (30%)     
   High risk (>20) 2832 (16%) 119 (37%)     
Morise score 11.3±3.25 12.7±2.84 1.98 [1.67, 2.36] 60 0.618 <0.001 
   Low risk (<9) 3492 (20%) 18 (6%)     
   Intermediate risk (9-15) 12203 (70%) 242 (76%)     
   High risk (>9) 1781 (10%) 57 (18%)     
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Table 3: Predictive Value of Degree of Stenosis and Plaque Composition 
Uncorrected Corrected for clinical risk 
CT parameter No death 
n=17476 
Death 
n=317 Hazard ratio C-index p-value C-index p-value 
Number of segments with  
any plaque or stenosis 2.1±2.7 3.7±2.87 1.22 [1.03, 1.44] 0.683 <0.0001 0.621 <0.0001 
Number of segments with 
stenosis >50% 0.45±1.06 1.1±1.58 1.17 [1.05, 1.29] 0.643 <0.0001 0.524 0.29 
Number of segments with 
stenosis >70% 0.15±0.56 0.46±0.99 1.26 [1.07, 1.48] 0.603 <0.0001 0.535 0.18 
        
Number of segments with 
noncalcified plaques 0.40±0.86 0.31±0.64 1.00 [0.84, 1.19] 0.502 0.9 0.501 0.99 
Number of segments with  
mixed plaques 0.77±1.62 1.52±1.9 1.06 [0.98, 1.15] 0.619 <0.0001 0.516 0.60 
Number of segments with 
calcified plaques 0.92±1.72 1.77±2.4 1.08 [1.01, 1.15] 0.642 <0.0001 0.550 0.10 
Number of segments with 
calcified or mixed plaques 1.69±2.44 3.28±2.68 1.41 [1.21, 1.65] 0.696 <0.0001 0.618 <0.0001 
        
Number of proximal segments 
with calcified or mixed plaques 0.32±0.65 0.77±0.87 1.39 [1.14, 1.70] 0.696 <0.0001 0.643 <0.0001 
Number of proximal segments 
with stenosis >50% 0.14±0.43 0.41±0.67 1.46 [1.15, 1.87] 0.652 <0.0001 0.563 0.04 
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Table 4: Incremental predictive value of proximal plaque in CCTA 
Model Net Reclassification from clinical risk 
 Parameter Coefficient p-value Test sample Validation sample 
Model 1: Clinical risk Base model Base model 
 NCEP ATP III risk 0.207 <0.0001   
Model 2: Clinical risk + CT parameters 49% (p<0.0001) 60% (p=0.0011) 
 NCEP ATP III risk 0.144 <0.0001   
 Proximal mixed or calcified plaque 0.407 0.0003   
 Proximal stenosis >50% 0.398 0.0001   
NCEP ATP III risk is formatted to represent 1 score point in the published point system. The first two proximal segments with calcified or 
mixed plaques and the first two proximal segments with a stenosis >50% are each equivalent to 2.8 points (16). For further details please 
refer to the statistical supplement. 
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